Standard Biotools earnings were $133.1M for the trailing 12 months ending Sep 30, 2026, with N/A growth year over year. The latest LAB earnings report on Sep 30, 2026 announced Q3 2026 earnings of $13.5M, down 150.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, LAB reported annual earnings of -$74.9M, with -59.5% growth.
What were Standard Biotools's earnings last quarter?
On LAB's earnings call on Nov 17, 2026, Standard Biotools (NASDAQ: LAB) reported Q3 2026 earnings per share (EPS) of $0.03, up 133.33% year over year. Total LAB earnings for the quarter were $13.48 million. In the same quarter last year, Standard Biotools's earnings per share (EPS) was -$0.09.
As of the last Standard Biotools earnings report, Standard Biotools is currently profitable. Standard Biotools's net profit (also called net income) for the twelve months ending Sep 30, 2026 was $133.08 million, a 203.76% decrease year over year.
What was LAB's earnings growth in the past year?
As of Standard Biotools's earnings date in Nov 17, 2026, Standard Biotools's earnings has grown year over year. LAB earnings in the past year totalled $133.08 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.